Skip to Main Content

Edwards Lifesciences Corporation (NYSE: EW) Securities Fraud Class Action

View Complaint
CompanyEdwards Lifesciences Corporation
CourtUnited States District Court for the Central District of California
Case Number24-cv-02221
JudgeHonorable Anne Hwang
Class PeriodFebruary 6, 2024 through July 24, 2024
Security TypeCommon Stock

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Edward Lifesciences Corporation (“Edwards”) (NYSE: EW) common stock between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”). 

Edwards is a medical technology company that develops, manufactures, and markets devices for structural heart disease, critical care, and surgical monitoring. Edwards’ primary product is the Transcatheter Aortic Valve Replacement (“TAVR”), which is a minimally invasive alternative procedure to open-heart surgery in certain circumstances. 

The Class Period begins on February 6, 2024, when Edwards issued its fourth quarter results. In connection with its results, the company published a press release, highlighting, in pertinent part, the significant progress that was made by the TAVR - stating that “Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent.”

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) TAVR volume had started declining as early as 2023; (2) TAVR sales growth was limited at least in part due to hospital capacity constraints; (3) hospitals were dedicating their limited resources to more time and cost efficient procedures other than the TAVR; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:
On October 21, 2025, Defendants filed an Answer to the Amended Complaint. This action is in the discovery phase and is ongoing.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.
 

Complete this form with your transactions in Edwards Lifesciences Corporation securities between February 6, 2024 and July 24, 2024.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Edwards Lifesciences Corporation prior to the Class Period?
Are you a current or former employee of Edwards Lifesciences Corporation?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter.
Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email